Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, April 28, 2015, 56 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $625.00 to $2,071,840.58.

Highlighted Stocks Traded by Insiders:

NASDAQ OMX Group (NDAQ) - FREE Research Report

Kloet Thomas A, who is Director at NASDAQ OMX Group, bought 2,000 shares at $48.46 on April 28, 2015. Following this transaction, the Director owned 2,000 shares meaning that the stake was boosted by 100% with the 2,000-share transaction.

The shares most recently traded at $49.01, up $0.55, or 1.12% since the insider transaction. Historical insider transactions for NASDAQ OMX Group go as follows:

  • 4-Week # shares sold: 10,231
  • 12-Week # shares sold: 154,307
  • 24-Week # shares sold: 204,005

The average volume for NASDAQ OMX Group has been 992,900 shares per day over the past 30 days. NASDAQ OMX Group has a market cap of $8.2 billion and is part of the financial sector and financial services industry. Shares are up 2.84% year-to-date as of the close of trading on Tuesday.

The NASDAQ OMX Group, Inc. provides trading, clearing, exchange technology, regulatory, securities listing, information, and public company services worldwide. It operates in four segments: Market Services, Listing Services, Information Services, and Technology Solutions. The stock currently has a dividend yield of 2.07%. The company has a P/E ratio of 26.1. Currently, there are 7 analysts who rate NASDAQ OMX Group a buy, no analysts rate it a sell, and 3 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on NDAQ - FREE

TheStreet Quant Ratings

rates NASDAQ OMX Group as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, reasonable valuation levels and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full

NASDAQ OMX Group Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

FireEye (FEYE) - FREE Research Report

King Alexa, who is SVP and General Counsel at FireEye, sold 5,000 shares at $44.75 on April 28, 2015. Following this transaction, the SVP and General Counsel owned 375,273 shares meaning that the stake was reduced by 1.31% with the 5,000-share transaction.

The shares most recently traded at $43.06, down $1.69, or 3.92% since the insider transaction. Historical insider transactions for FireEye go as follows:

  • 4-Week # shares sold: 5,000
  • 12-Week # shares sold: 26,292
  • 24-Week # shares sold: 30,085

The average volume for FireEye has been 6.5 million shares per day over the past 30 days. FireEye has a market cap of $6.8 billion and is part of the technology sector and computer software & services industry. Shares are up 36.16% year-to-date as of the close of trading on Tuesday.

FireEye, Inc., together with its subsidiaries, provides cybersecurity solutions for detecting, preventing, and resolving cyber-attacks. Currently, there are 11 analysts who rate FireEye a buy, 1 analyst rates it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on FEYE - FREE

TheStreet Quant Ratings

rates FireEye as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, generally disappointing historical performance in the stock itself and feeble growth in its earnings per share. Get the full

FireEye Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Hemispherx Biopharma (HEB) - FREE Research Report

Equels Thomas K., who is CFO, Vice Chairman, Secretary at Hemispherx Biopharma, bought 100,000 shares at $0.24 on April 28, 2015. Following this transaction, the CFO, Vice Chairman, Secretary owned 1.3 million shares meaning that the stake was boosted by 8.3% with the 100,000-share transaction.

The shares most recently traded at $0.25, up $0.01, or 2.28% since the insider transaction. Historical insider transactions for Hemispherx Biopharma go as follows:

  • 4-Week # shares bought: 400,000
  • 12-Week # shares bought: 400,000
  • 24-Week # shares bought: 400,000

The average volume for Hemispherx Biopharma has been 2.1 million shares per day over the past 30 days. Hemispherx Biopharma has a market cap of $49.7 million and is part of the health care sector and drugs industry. Shares are down 7.52% year-to-date as of the close of trading on Tuesday.

Hemispherx Biopharma, Inc., a specialty pharmaceutical company, engages in the clinical development of new drug therapies based on natural immune system enhancing technologies for the treatment of viral and immune based chronic disorders in the United States. Currently, there are no analysts who rate Hemispherx Biopharma a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on HEB - FREE

TheStreet Quant Ratings

rates Hemispherx Biopharma as a

sell

. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and generally disappointing historical performance in the stock itself. Get the full

Hemispherx Biopharma Ratings Report

from

TheStreet Quant Ratings

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null